• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

breast cancer

topic report
National Breast Cancer Awareness Month pink ribbon
Biotech

After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs

From dual-payload ADCs to bispecifics and radioligands, drugmakers are hunting for answers either after Enhertu progression or to replace it.
Angus Liu Oct 28, 2026 9:00am
BioNTech

BioNTech sees limited ADC benefit as ph. 3 shows modest efficacy

Oct 26, 2026 8:39am
breast cancer mammogram

SimBioSys nabs FDA OK for AI breast cancer recurrence tool

Oct 16, 2026 9:00am
AZ
Favicon Fierce Pharma

FDA's surprise approval of AZ's oral SERD sets new paradigm

Sep 8, 2026 10:35am
ESMO AstraZeneca

Guardant wins FDA nod for test guiding AstraZeneca’s Etcamah

Sep 7, 2026 2:08am
Celcuity
Favicon Fierce Pharma

Celcuity set to be Big Pharma 'strategic target' after approval

Jul 14, 2026 4:56pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings